Biotecnol
Corporate Presentation
JosĂŠ LuĂs Moreira, Ph.D., MBA
Therapies for life
Chief Financial Officer & Chief Operational Officer
Development of new drugs
Development of new drugs
Research institutions
Development of new drugs
Multinational pharma corps.
Development of new drugs
Multinational pharma corps.
Development of new drugs
Biotec sme’s Biotecnol
Core Business
proprietary products strategy (long term)
services tactics (short term) 7
Core Business
oncology
● improved products to known targets
MoABs Biotecnol
● new products to new targets
2003 – ... hepathology Biotecnol
new pharma products
1998 – ...
● services to other
products
processes platforms
know-how
partnerships technologies
companies ● production of their own products ● optimization of production process ● as a service supply or in partnership 8
Corporate Organization
sa
inc
www.biotecnol.com
sa
www.rodonbiologics.com
Corporate Organization
Rodon Biologics
New Brunswick, NJ (USA)
Oeiras (Portugal)
Corporate Organization
Third party SA Potential Biotecnol outsourcing competitors
Out-licensing and own Tribody pipeline
Subcontracted Tribody development services
Non Tribody services to 3rd parties
Rodon Biologics
Tribody Platform IP US management Know-How Protocols SOP’s Commercial and R&D contracts
Site in New Brunswick, NJ
• Preclinical
Site in Oeiras, PT
• Process
development
development and manufacturing
• Future clinical
• Quality Control
development
System
Fully equipped laboratories Highly qualified and experienced scientists
State of the art R&D centre
• First Portuguese biopharmaceutical company to establish its activity outside a public R&D institute and become fully independent • Full internal capabilities for biological products development and manufacturing
State of the art R&D centre
Effective process development Technology
Economics
Manufacturing Business PROCESS Quality Control
Engineering
DEVELOPME NT Scale-up
Quality Assurance
Regulatory Affairs
Supply Chain and Logistics
Collaboration and technology licensing
Naples University
3rd party services
3rd party services
Product IL-13
Indication Uvidem速
Cardiotrophin1 transplants VB6-845-CL
oncology
GMCFS
stroke
Interferon
ACV
Bavituximab
HCV
ACE393
vaccine
Anti-Hsp90
metastatic melanoma
NS3
Hepatitis C
FastScreen ADC-1004
Stroke, trauma
Pro.insulin
Retinitis pigmentosa
R&D
Pre-clinic
Phase I
Phase II
Phase III
Partner
Tribody Platform single antigen target molecules CD3
CD19
CD3
CD19
CD20
CD3
CD20
X
X
dual antigen target molecules CD3
CD19
CD3
CD20
CD19
CD3
X
CD20
X
Contacts
Biotecnol, SA Lagoas Park Edifício 7,1º Norte 2741-901 Oeiras Portugal
Biotecnol Pharmaceuticals, Inc 675 US Highway OneNorth Brunswick, NJ 08902 USA USA
jlm@biotecnol.com www.biotecnol.com www.rodonbiologics.com 19